Table 4:
Our estimates of Euroquol 5-dimension (EQ5D) utility based on ambulatory status in the context of other studies examining health-related quality of life in other cancer-based, spine and musculoskeletal conditions.
| Study | Condition | Sample Size | Utility |
| Spross et al16 | Proximal humerus fracture | 192 | 0.88 |
| Davies et al20 | Head and Neck cancer | 2,065 | 0.87 |
| Doherty et al21 | Esophageal cancer | 199 | 0.80 |
| Current study | Spinal metastases: Independently ambulatory | 430 | 0.76 |
| Versteeg et al1 | Spinal metastases: Non-operative cohort | 84 | 0.66 |
| Current study | Spinal metastases: Ambulatory with assistance | 205 | 0.59 |
| Versteeg et al1 | Spinal metastases: operative cohort | 136 | 0.52 |
| Smith et al17 | Adult cervical deformity | 121 | 0.51 |
| Miyazaki et al11 | Spinal metastases: operative cohort at 12-months | - | 0.45 |
| De Ruiter et al12 | Spinal metastases: Presentation | 113 | 0.44 |
| Burgstaller et al18 | Lumbar spinal stenosis pre-treatment | 364 | 0.40 |
| Morgen et al13 | Spinal metastases: operative cohort at enrollment | 69 | 0.28 |
| Current study | Spinal metastases: Non-ambulatory | 40 | 0.14 |
| Miyazaki et al11 | Spinal metastases: operative cohort at enrollment | 31 | 0.04 |